Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
778 Results for "
Stat3
" in MedChemExpress (MCE) Product Catalog:
Products (778)
778 Results for "Stat3" in MCE Product Catalog:
Cat. No.: HY-40354H
CAS No.: 1803005-18-6
Synonyms: Tasocitinib hydrochloride; CP-690550 hydrochloride
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology
Tofacitinib hydrochloride (Tasocitinib hydrochloride) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib hydrochloride blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib hydrochloride can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury [3] .
Cat. No.: HY-40354R
CAS No.: 477600-75-2
Synonyms: Tasocitinib (Standard); CP-690550 (Standard)
Target:
Tofacitinib (Standard) (Tasocitinib (Standard); CP-690550 (Standard)) is the analytical standard of Tofacitinib (HY-40354). This product is intended for research and analytical applications. Tofacitinib (Tasocitinib) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury [3] .
Cat. No.: HY-40354S
CAS No.: 2256762-71-5
Synonyms: Tasocitinib-13C3; CP-690550-13C3
Target:
Tofacitinib- 13C3 (Tasocitinib- 13C3; CP-690550- 13C3) is the 13C-labeled Tofacitinib (HY-40354). Tofacitinib (Tasocitinib) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury [3] .
Cat. No.: HY-40354S1
Synonyms: Tasocitinib-13C3,15N; CP-690550-13C3,15N
Target:
Tofacitinib- 13C3, 15N (Tasocitinib- 13C3, 15N; CP-690550- 13C3, 15N) is the 15N, 13C-labeled Tofacitinib (HY-40354). Tofacitinib (Tasocitinib) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury [3] .
Cat. No.: HY-40354S2
Synonyms: Tasocitinib-13C,d3; CP-690550-13C,d3
Target:
Tofacitinib- 13C,d3 (Tasocitinib- 13C,d3; CP-690550- 13C,d3) is the deuterated, 13C-labeled Tofacitinib (HY-40354). Tofacitinib (Tasocitinib) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury [3] .
Cat. No.: HY-40354S3
Synonyms: Tasocitinib-13C; CP-690550-13C
Target:
Tofacitinib- 13C (Tasocitinib- 13C; CP-690550- 13C) is the 13C-labeled Tofacitinib (HY-40354). Tofacitinib (Tasocitinib) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury [3] .
Cat. No.: HY-40354S5
Synonyms: Tasocitinib-d3; CP-690550-d3
Target:
Tofacitinib-d3 (Tasocitinib-d3; CP-690550-d3) is the deuterated-labeled Tofacitinib (HY-40354). Tofacitinib (Tasocitinib) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury [3] .
Cat. No.: HY-180766
JAK2-IN-19 (Compound 3p) is a JAK2 inhibitor with a KD value of 1.11 μM. JAK2-IN-19 inhibits the proliferation of K562 cells and HeLa cells. JAK2-IN-19 significantly reduces the level of p-JAK2. JAK2-IN-19 can be used for research on cervical cancer and leukemia .
Cat. No.: HY-P990016
CAS No.: 2639874-57-8
Synonyms: ARGX-112; LEO-138559; LP-0145
Target:
Research Areas:
Cat. No.: HY-N0204
CAS No.: 129724-84-1
Synonyms: Anemoside A3
Cat. No.: HY-N20713
CAS No.: 118524-14-4
Category:
Cat. No.: HY-153188A
CAS No.: 2755075-91-1
Target:
Research Areas:
(S)-JNJ-1013 is an isomer of IRAK1 PROTAC degrader JNJ-1013 (HY-153188). (S)-JNJ-1013 loses VHL binding affinity (IC50 >10 μM) and shows no significant IRAK1 degradation activity (DC50 > 10 μM). (S)-JNJ-1013 selectively inhibits IRAK1 with an IC50 of 79 nM. (S)-JNJ-1013 can be used to study cancers dependent on the scaffolding function of IRAK1 .
Cat. No.: HY-167673
CAS No.: 1807639-36-6
Target:
Research Areas:
RNF5-IN-1 is a selective small-molecule inhibitor and degrader of the E3 ubiquitin ligase RNF5. RNF5-IN-1 directly binds to the N-terminal cytosolic domain of RNF5 with a KD of 594 nM, inhibits the E3 ubiquitin ligase activity of RNF5, and exhibits selectivity over Hrd1 and Praja1. RNF5-IN-1 promotes the degradation of RNF5 via the p97/VCP-dependent endoplasmic reticulum-associated degradation (ERAD) and proteasome pathway. RNF5-IN-1 inhibits the retrotranslocation of misfolded proteins. RNF5-IN-1 is applicable for research on mechanisms related to cystic fibrosis .
Cat. No.: HY-171825
CAS No.: 2570251-63-5
Research Areas:
SIAIS001 is a CRBN-dependent ALK PROTAC degrader with a DC50 of 3.9 nM. SIAIS001 induces ALK protein degradation via the ubiquitin-proteasome system. SIAIS001 induces G1/S phase cell cycle arrest and inhibits proliferation of cancer cells. SIAIS001 can be used for the research of anaplastic large-cell lymphomas .
Cat. No.: HY-168894
Target:
Ferroptosis JAK STAT p38 MAPK AMPK GSK-3 Apoptosis HSP TNF Receptor
Research Areas:
Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
CT-1 is a secreted protein belonging to the IL-6 cytokine family. Overexpression of CT-1 enhances cell proliferation, migration and angiogenesis via the ADMA/DDAH pathway. CT-1 inhibits the growth of triple-negative breast cancer cells by simultaneously inducing Ferroptosis in N2-type tumor-associated neutrophils and cancer cells. CT-1 activates the Jak/STAT-3, p42/p44 MAPK and AMPK pathways, and inhibits GSK-3β activity through phosphorylation to induce cardiomyocyte hypertrophy. CT-1 enhances the viability of cardiomyocytes and neurons, reduces cell Apoptosis, induces the expression of heat shock proteins (HSP) and BNP, and inhibits TNF levels. CT-1 exerts anti-tumor activity in mouse models of triple-negative breast cancer. CT-1 improves cognitive impairment in mice. CT-1 is applicable to the research of ischemic heart disease, triple-negative breast cancer, myocardial hypertrophy, Parkinson's disease, hypertensive heart disease, myocardial infarction, acute Chagas cardiomyopathy, high-fat diet-induced cognitive impairment and diabetes-related cognitive impairment [3] .
Cat. No.: HY-183519
CAS No.: 118499-11-9
AH057 is an orally active JAK1 and JAK2 inhibitor. AH057 blocks IL-6-, IFN-α- and IFN-γ-induced JAK/STAT signaling, reduces cancer cell proliferation, invasion and colony formation, and induces apoptosis and G1 cell-cycle arrest. AH057 can be used for cervical cancer research .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
